The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)-Reference-Cited by-同舟云学术

The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)

Published:2014-11-25 Issue:4 Volume:36 Page:2491-2499
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Ding Lingyu,Liu Kejun,Jiang Zhelong,Chen Qi,Zhou Ningning,Liang Ying,Gao Hongfei,Hong Xiangchan,Wu Haiying

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-014-2862-4.pdf

Reference42 articles.

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA: Cancer J Clin. 2005;55(1):10–30.

2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(21):3543–51. doi: 10.1200/JCO.2007.15.0375 .

3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. doi: 10.1056/NEJMoa011954 .

4. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19(13):3210–8.

5. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2000;18(1):122–30.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-angiogenesis: Opening a new window for immunotherapy;Life Sciences;2020-10

2. First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China;Chinese Journal of Cancer Research;2019

3. Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab;Cardiovascular Toxicology;2018-05-08

4. Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis;Oncology Letters;2018-02-15

5. A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC);Tumor Biology;2016-03-25